Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.

Autor: Verdoia M; Division of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, Italy.; Department of Translational Medicine, Eastern Piedmont University, Novara, Italy., Nardin M; Department of Translational Medicine, Eastern Piedmont University, Novara, Italy.; Department of Medicine, Spedali Civili of Brescia, Brescia, Italy., Gioscia R; Division of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, Italy., Suryapranata H; Department of Cardiology, UMC St Radboud, Nijmegen, the Netherlands., Kedhi E; Department of Cardiology, ISALA Hospital, Zwolle, the Netherlands., Rognoni A; Division of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, Italy., DE Luca G; Division of Clinical and Experimental Cardiology, University Hospital of Sassari, Sassari, Italy - gdeluca@uniss.it.
Jazyk: angličtina
Zdroj: Minerva cardiology and angiology [Minerva Cardiol Angiol] 2023 Jun; Vol. 71 (3), pp. 257-265. Date of Electronic Publication: 2022 Oct 12.
DOI: 10.23736/S2724-5683.22.06001-X
Abstrakt: Background: No study has so far evaluated the impact of chronic kidney disease (CKD) on high-on treatment platelet reactivity (HRPR) with ticagrelor and their prognostic consequences, that were therefore the aim of the present study.
Methods: Patients on dual antiplatelet therapy with ASA+ticagrelor (90mg/twice a day) after percutaneous coronary revascularization for ACS were scheduled for platelet function assessment 30-90 days post-discharge. The primary study endpoint was defined as the occurrence of major cardiovascular events (a composite of cardiovascular death, recurrent acute coronary syndrome (MI), target vessel revascularization) at the longest available follow-up.
Results: We included 396 patients, that were divided according to CKD (eGFR Conclusions: In the present study we demonstrated that among ACS patients on DAPT with ASA and ticagrelor after PCI, renal failure is not associated with a higher rate of HRPR or to an increased risk of mortality or major ischemic and bleeding events.
Databáze: MEDLINE
Externí odkaz: